ArticleJournal of virology2004
Development of a GB virus B marmoset model and its validation with a novel series of hepatitis C virus NS3 protease inhibitors.
Article in Journal of virology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 87 citations in OpenAlex.
- Marmosets as models of infectious diseases.Frontiers in cellular and infection microbiology · 2024Review
- Review
- GB Virus B and Hepatitis C Virus, Distantly Related Hepaciviruses, Share an Entry Factor, Claudin-1.Journal of virology · 2023Article
- Early Phase of Specific Cellular Immune Status Associates with HCV Infection Outcomes in Marmosets.Viruses · 2023Article
- Utility of Common Marmoset (Genes · 2020Review
- Non-Human Primate Models of Dengue Virus Infection: A Comparison of Viremia Levels and Antibody Responses during Primary and Secondary Infection among Old World and New World Monkeys.Pathogens (Basel, Switzerland) · 2020Review
- Marmoset Viral Hepatic Inflammation Induced by Hepatitis C Virus Core Protein via IL-32.Frontiers in cellular and infection microbiology · 2020Article
- Three asymptomatic animal infection models of hemorrhagic fever with renal syndrome caused by hantaviruses.PloS one · 2019Article
- Animal Models to Study Hepatitis C Virus Infection.Frontiers in immunology · 2018Review
- Article
- Metabolic Dysregulation in Hepacivirus Infection of Common Marmosets (Callithrix jacchus).PloS one · 2017Article
- Acute Liver Damage Associated with Innate Immune Activation in a Small Nonhuman Primate Model of Hepacivirus Infection.Journal of virology · 2016Article
- Infection of Common Marmosets with GB Virus B Chimeric Virus Encoding the Major Nonstructural Proteins NS2 to NS4A of Hepatitis C Virus.Journal of virology · 2016Article
- Susceptibility of Marmosets (Callithrix jacchus) to Monkeypox Virus: A Low Dose Prospective Model for Monkeypox and Smallpox Disease.PloS one · 2015Article
- NS2 proteins of GB virus B and hepatitis C virus share common protease activities and membrane topologies.Journal of virology · 2014Article
- Changes in immune cell populations in the periphery and liver of GBV-B-infected and convalescent tamarins (Saguinus labiatus).Virus research · 2014Article
- Modeling HCV disease in animals: virology, immunology and pathogenesis of HCV and GBV-B infections.Frontiers in microbiology · 2014Review
- A novel hepacivirus with an unusually long and intrinsically disordered NS5A protein in a wild Old World primate.Journal of virology · 2013Article
- Article
- The marmoset monkey: a multi-purpose preclinical and translational model of human biology and disease.Drug discovery today · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
GB virus B (GBV-B), a flavivirus closely related to HCV, has previously been shown to infect and replicate to high titers in tamarins (Saguinus sp.). This study describes the use of GBV-B infection and replication in the common marmoset (Callithrix jacchus) for the successful development and validation of a surrogate animal model for hepatitis C virus (HCV). Infection of marmosets with GBV-B produced a viremia that peaked at 10(8) to 10(9) genome copies/ml for a period of 40 to 60 days followed by viral clearance at 60 to 80 days postinfection. Passage of the initial tamarin-derived GBV-B in marmosets produced an infectious stock that gave a more reproducible and consistent infection in the marmoset. Titration of the virus stocks in vivo indicated that they contained 1 infectious unit for every 1,000 genome copies. Cultures of primary marmoset hepatocytes were also successfully infected with GBV-B, with high levels of virus detected in supernatants and cells for up to 14 days postinfection. Treatment of GBV-B-infected hepatocyte cultures with a novel class of HCV protease inhibitor (pyrrolidine 5,5 trans-lactams) reduced viral levels by more than 2 logs. Treatment of GBV-B-infected marmosets with one such inhibitor resulted in a 3-log drop in serum viral titer over 4 days of therapy. These studies provide the first demonstration of the in vivo efficacy of a small-molecule inhibitor for HCV in an animal model and illustrate the utility of GBV-B as a surrogate animal model system for HCV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.